Canada Markets close in 2 mins

Paratek Pharmaceuticals, Inc. (PRTK)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.8800-0.0800 (-4.08%)
As of 03:57PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.9600
Open1.9300
Bid1.9200 x 900
Ask1.9300 x 1200
Day's Range1.8450 - 2.0150
52 Week Range1.7900 - 11.2400
Volume407,605
Avg. Volume555,729
Market Cap94.355M
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateOct 31, 2014
1y Target EstN/A
  • GlobeNewswire

    Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

    BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Evan Loh, M.D., chief executive officer, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference. The conference will b

  • GlobeNewswire

    Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million

    -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021 -- Omadacycline Demonstrated Potent In Vitro Efficacy Against Mycobacterium Avium Complex (MAC) in a Hollow Fiber Model BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today reported financial results and provided an update on corporate activities for the quarter ended March 31, 2022. “Our commercial execution continue

  • GlobeNewswire

    Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on April 29, 2022, the Company granted stock options to one new employee of the Company. This award was granted pursuant to the Paratek Pharmaceuticals, Inc. 2017